Regenxbio (RGNX) said Wednesday that new interim data from two additional patients with Duchenne muscular dystrophy in a phase 1/2 study of investigational gene therapy RGX-202 added to "consistent, robust" microdystrophin and transduction levels across all treated ages.
The company said microdystrophin expression was measured at 122.3% in a 3-year-old patient and 31.5% in a 7-year-old patient compared to control.
Regenxbio said it is enrolling ambulatory patients 1 year old and older for a phase 3 trial and is on track to submit a biologics license application with the US Food and Drug Administration in mid-2026.
Shares of the company were up more than 5% in recent trading.
Price: 8.20, Change: +0.40, Percent Change: +5.13
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。